Abstract: Compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application.

Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: The present invention relates to a method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents, to the solubilisate produced by this method and respective uses as a dietary supplement or pharmaceutical dosage form. A phosphatidylcholine-based solubilization method is disclosed.

Abstract: Formulations for topical use based on vitamin E or an ester thereof for use in removing, reducing or inhibiting a bacterial and/or fungal biofilm, are disclosed. The ester of vitamin E is an ester with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having from 1 to 19 carbon atoms, or an alkenyl or alkynyl having from 2 to 19 carbon atoms.

Abstract: A polyalkylene glycol having an end-group of the general formula: in which each R2 independently represents a hydroxyl, alkyl, alkenyl, aryl, heteroaryl, benzyl, or polyalkylene glycol group, and each R3 independently represents a hydroxyl, alkyl, alkenyl, aryl, heteroaryl, benzyl, or polyalkylene glycol group; m is 0, 1, 2, 3, 4, 5 or 6; and n is 0, 1, 2 or 3. A lubricating oil composition comprising this polyalkylene glycol. A refrigerant composition comprising this polyalkylene glycol. A method of lubricating moving parts of an industrial or automotive system comprising applying a composition to the parts, wherein the composition comprises this polyalkylene glycol.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: An apparatus may include a processor caused to: receive indications of selection of an experiment design for regression analysis, of a type of distribution for a simulation of random data in the regression analysis, and of selection of a number of iterations of the simulation of random data; generate executable instructions in a pre-selected programming language to be executable by the processor to perform the regression analysis with the selected number of iterations of simulation of random data and with the selected type of distribution; generate a human readable form of a portion of the first executable instructions that includes the coefficients and terms in mathematical notation, and that specifies the selected number of iterations and the selected type of distribution for the simulation of random data; and present, on a display communicatively coupled to the processor, the human readable form of the portion of the first executable instructions.

Abstract: A dietary supplement composition provided synergistic effects of xanthorrhizol and tocotrienol on malignancies. A blend of xanthorrhizol and delta tocotrienol achieved 69% growth suppression of melanoma, exceeding the sum of individual effects. In prostate cancer, 90% growth suppression was achieved by a blend of xanthorrhizol and delta tocotrienol; however, the same 90% of growth suppression was achieved by 3-fold xanthorrhizol and 1.8-fold delta tocotrienol respectively, which indicated synergistic impact of the two agents. Mechanisms of action for the anticancer property showed synergism of xanthorrhizol and tocotrienol-mediated cancer growth suppression was attributed to cell cycle arrest, at the G1 phase of cell cycle, and apoptosis. This novel dietary supplement combination of xanthorrhizol to tocotrienol (1:1 to 10:1) may provide benefits to individuals consuming it on a regular or periodic basis.

Abstract: Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, wherein upon mixing of the composition of matter with water the tocotrienol based composition is substantially emulsified; and wherein upon mixing of the composition of matter with water a resulting emulsion has an intensity-weighed mean droplet size of less than 700 nm are also disclosed.

Abstract: To provide a new preventive or therapeutic agent for age-related macular degeneration. The present invention relates to a preventive or therapeutic agent for age-related macular degeneration containing a BLT1 antagonist or a LTB4 biosynthesis inhibitor as an active ingredient. The administration form of the preventive or therapeutic agent for age-related macular degeneration of the present invention includes eye drops, injections, oral agents (tablets, granules, dispersions, capsules), ointments, and creams. The form of these pharmaceutical compositions can be formulated by combining with a pharmaceutically acceptable carrier.

Abstract: The invention is concerned with food products comprising one or more cocoa bean products and a carotenoid compound, particularly with food products which are, or comprise, chocolate. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation.

Abstract: An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.

Abstract: Method of enhancing the bioavailability of a tocotrienol to a human for treating a disease or condition amenable to treatment with a tocotrienol, by administering a composition formulated for transmucosal delivery to the human. The composition contains at least one tocotrienol, and the disease or condition is selected from post-exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy and a condition resulting from radiation exposure.

Abstract: A foaming oil cleanser composition and a method of preparing a foaming oil cleanser composition are provided. The foaming oil cleanser composition includes (a) a dialkyl sulfosuccinate, (b) Ricinus Communis Seed Oil, and (c) one or more oils. The foaming oil cleanser composition is essentially free of water and sulfate.

Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

Abstract: This invention is in the field of micro-organism and algal cell processing. The invention relates to a method of maximizing migration of micro-organism and/or algal cells to a solvent fraction while simultaneously displacing water in a separate fraction and subsequent extraction of hydrophobic products from the organisms. The invention further relates to a method of sequestration of protein from an aqueous phase to an organic solvent.

Abstract: In present invention oxidation method of viscon cellulose with NO2 obtained H3PO4/HNO3 is defined liquid and gas media. Regenerated oxidise cellulose (REOC in shorten term) contain in —COOH yields are standardised as 18.6-20.1 for textile, 19.8-21.5% for powder samples. Powder and textile (woven and fabric) products are impregnated 1.8-2.4% Ca+2 ion, 0-1.1% Na+1 ion, 0.8-1.5% tranexamic acid and 6-aminocaproic acid as antifibrinolytic. Obtained powder and gel products are impregnated Bi+3, Zn+2 and Ag+1 ions for antiseptic purposes. Only Bismuth of them is shown antibacterial effects. Also the aim of present invention is haemostat antimicrobial properties during impregnation of Rifampicin, Gatifloxacin, Doxycycline, Levofloxacin, Lincomycin, Clindamycin, Ciprofloxacin. Haemostatic properties are indicated for all products and antimicrobial properties are shown for some samples. Cytotoxicity, sensitivity and irritation properties are determined in compliance of Pharmacopeias.

Abstract: The present invention relates to improved vitamin E formulations, as well as to the production of such formulations.

Abstract: The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.

Abstract: The present disclosure relates to compositions containing a natural extract(s) and their fraction(s) and the use of such compositions for treatment of skin, hair and nail. For example, the present disclosure relates to compositions containing an aqueous extract of (i) Yacon leave, (ii) Amor Seco leave, or (iii) Porphyridium biomass, or a combination thereof and a pharmaceutically or cosmetically acceptable carrier use on hair skin and nails for cosmetic purposes.

Abstract: The present invention relates to epoxy-tigliane compounds and their use in promoting wound healing. In particular embodiments, the epoxy-tigliane compounds are epoxy-tigliaen-3-one compounds. Methods of inducing or promoting wound healing as well as methods of reducing scarring and improving cosmetic outcomes upon healing of a wound are described. Compounds and compositions for use in wound healing are also described.

Abstract: The present disclosure relates to compositions and methods for providing full spectrum photo protection to skin, which includes protection from infrared (IR) radiation and/or visible light in addition to protection from UV radiation. The compositions typically include: (a) silymarin; (b) one or more antioxidants selected from the group consisting of ferulic acid, Vitamin C, polydatin, and hesperetin; (c) optionally, one or more solubilizers; and (d) a cosmetically acceptable carrier. The compositions are unique in that the combination of (a), (b), optional (c), and (d) alone, provide at least full spectrum protection from ultraviolet radiation (UV), visible light, and infrared radiation (IR). The composition can additionally, optionally, include one or more UV filters to further enhance protection from UV radiation.

Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of ? tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol in combination with cyclodextrin to a patient in need thereof.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B2, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, calcium, magnesium, zinc, boron and chromium in one or more specified ratios.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract: The present invention relates to a composition containing riboflavin and a sesamin-class compound(s). This composition may incorporate a sesamin-class compound(s) in such an amount that the proportion (weight ratio) of its total quantity to the total quantity of riboflavin taken as unity is no more than 4.5, and it has the advantage that the analgesic and anti-fatigue actions of riboflavin are synergistically improved by ingestion of riboflavin in combination with a sesamin-class compound(s). The composition of the present invention provides compositions, in particular, pharmaceuticals as well as foods and beverages that are safe to humans, animals, etc., and can therefore be ingested for a continued period, and which have far superior effects to those of conventional foods having an analgesic or anti-fatigue action.

Abstract: Compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. Compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Abstract: Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 ?m is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.

Abstract: A process for determining the incompatibility of crude mixtures (heavy, light) is based on the measurement of dynamic viscosity of crude mixtures using an electromagnetic viscometer having a mobile element (piston) move through the fluid to be measured at a constant force.

Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

Abstract: Animate surface treatment compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a metal ion source material which releases copper ions and/or zinc ions into the treatment composition, in certain embodiments at least one alcohol which independently of other constituents present exhibits a microbicidal effect, in certain embodiments at least one quaternary ammonium compound which provides a microbicidal benefit, optionally but very preferably also at least one detersive surfactant, further optionally one or more further constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants, and water, wherein the compositions are at a pH such that the animate surface treatment compositions, exhibit a microbicidal or germicidal or antimicrobial effect on treated surfaces, which compositions are characterized in exhibiting a microbicidal benefit when tested against one or more challeng

Abstract: A method of determining relative polyphenol antioxidant levels in plant matter, particularly whole sorghum seeds, is carried out by combining a selected amount of solid plant matter to be evaluated with a solvent and a polyphenol extraction agent to form a stirrable mixture. The mixture is heated to approximately the boiling point of the solvent with agitation of the mixture for a period of at least 1½ hours. The heated mixture is filtered while the liquid is at a temperature of not more than 5° C. below the boiling point of the solvent to obtain an extractant solution filtrate. From this filtrate, a concentrated extractant solution is formed, cooled, and filtered to form a final filtrate. An analytical sample of this final filtrate is then introduced into a high performance liquid chromatography (HPLC) system to separate and determine the relative amounts of polyphenol antioxidants in the plant matter.

Abstract: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.

Abstract: A water-based pigmented preparation, its production and use and its application in a capillary storage system.

Abstract: The invention encompasses intravenous pharmaceutical compositions containing omega-3 fatty acids and methods of treating traumatic brain injury, traumatic spinal cord injury and/or stroke using these pharmaceutical compositions.

Abstract: A therapeutic liposome including a bilayer comprising at least one poly-unsaturated fatty acid (omega-3 fatty acid, omega-6 fatty acid, and omega-9 fatty acid), a beta-glucan, a cholesterol, and a doxorubicin. The liposome has a diameter of 100 nm to 1.5 ?m. The beta-glucan and the doxorubicin are encapsulated in the liposome and the cholesterol is integral to the bilayer of the liposome.

Abstract: Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable preservatives.

Abstract: A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars and purpura, among other skin diseases or conditions.

Abstract: The present invention relates to a compound as represented by formula (I), which is a condensation product of a theanine derivative and a carboxylic acid coumarin derivative, compounds as represented by formula (II) and formula (III), both of which are intermediates of the condensation product, a method for preparing these compounds, a pharmaceutical composition comprising the compounds, and a use thereof in preparing a medicament for prevention and treatment of tumors, inflammation, cardiovascular diseases, immune deficiency diseases and the like.

Abstract: The invention is generally directed to a process of producing purified gamma- and/or delta-tocotrienols from tocol-rich oils or distillates, such as rice bran oil deodorizer distillate or palm oil. The process produces a gamma- and/or delta-tocotrienol-rich fraction in a high proportion of ?-T3 and/or ?-T3 while minimizing the presence of alpha isomers from the tocol-rich oil or distillate. The ?-T3- and/or ?-T3-rich fraction comprises about 95% of total tocols, with the process yielding ?-T3 in approximately 10% and ?-T3 in about 3%, with each having purity in excess of approximately 95%. The process utilizes flash or other low pressure chromatography to provide rapid isolation of gamma- and/or delta-tocotrienol from the tocol-rich oil or distillate.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Abstract: Methods of treating or suppressing oxidative stress disorders affecting normal electron flow in the cells, including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases, diseases of aging and diseases caused by reactive oxygen species are disclosed, as well as compounds useful in the methods of the invention, such as such as catechol or ortho-quinone derivatives of Formula (I).

Abstract: The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol.

Abstract: Disclosed herein is a microemulsifying system consisting essentially of coconut oil and Polysorbate 80 in a specific weight ratio. Also disclosed herein are microemulsion preconcentrates and microemulsions that contain a lipophilic functional ingredient formulated with the microemulsifying system. Processes for preparing the microemulsion preconcentrates and microemulsions are also disclosed herein.

Abstract: The present invention relates to a stable oral pharmaceutical composition with improved solubility and bioavailability; comprising a taxoid, a solubilizer, a stabilizing agent, a surfactant(s), a solvent(s), and an oil wherein the concentration of taxoid is in the range of 0.1 to 10%.